Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

被引：3
|
作者：
Gouda, M. A. [1 ]
Hu, M. I. [2 ]
Cabanillas, M. E. [2 ]
Wu, J. [3 ,4 ]
Meric-Bernstam, F. [1 ]
Subbiah, V. [1 ,5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX USA
[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA
[5] Sarah Cannon Res Inst, Early Phase Drug Dev, Nashville, TN 37203 USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷 / 10期
基金：
美国国家卫生研究院;
关键词：
CACHEXIA; PATHWAY;
D O I：
10.1016/j.annonc.2023.07.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：946 / 948
页数：3
相关论文
共 50 条
  • [1] Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers.
    Gouda, Mohamed Alaa
    Ahmed, Jibran
    Nelson, Blessie Elizabeth
    Nardo, Mirella
    Roszik, Jason
    Cabanillas, Maria E.
    Hu, Mimi I-Nan
    Busaidy, Naifa Lamki
    Sherman, Steven I.
    Dadu, Ramona
    Naing, Aung
    Karp, Daniel D.
    Ahnert, Jordi Rodon
    Hong, David S.
    Elamin, Yasir Y.
    Blumenschein, George R.
    Heymach, John
    Meric-Bernstam, Funda
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers
    Nardo, Mirella
    Gouda, Mohamed A.
    Nelson, Blessie E.
    Barreto, Carmelia M. N.
    Slade, J. Hoyt
    Poullard, Anna
    Zafereo, Mark
    Hu, Mimi I.
    Cabanillas, Maria E.
    Subbiah, Vivek
    CELL REPORTS MEDICINE, 2023, 4 (12)
  • [3] Selective RET kinase inhibition for patients with RET-altered cancers
    Subbiah, V.
    Velcheti, V.
    Tuch, B. B.
    Ebata, K.
    Busaidy, N. L.
    Cabanillas, M. E.
    Wirth, L. J.
    Stock, S.
    Smith, S.
    Lauriault, V.
    Corsi-Travali, S.
    Henry, D.
    Burkard, M.
    Hamor, R.
    Bouhana, K.
    Winski, S.
    Wallace, R. D.
    Hartley, D.
    Rhodes, S.
    Reddy, M.
    Brandhuber, B. J.
    Andrews, S.
    Rothenberg, S. M.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1869 - 1876
  • [4] Precision therapy for RET-altered cancers with RET inhibitors
    Thein, Kyaw Z.
    Velcheti, Vamsidhar
    Mooers, Blaine H. M.
    Wu, Jie
    Subbiah, Vivek
    TRENDS IN CANCER, 2021, 7 (12) : 1074 - 1088
  • [5] RET kinase inhibitors for RET-altered thyroid cancers
    Vodopivec, Danica M.
    Hu, Mimi I.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [6] Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis
    Kairemo, Kalevi
    Macapinlac, Homer A.
    Gouda, Mohammed
    Subbiah, Vivek
    DIAGNOSTICS, 2024, 14 (17)
  • [7] Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
    Adashek, Jacob J.
    Desai, Aakash P.
    Andreev-Drakhlin, Alexander Y.
    Roszik, Jason
    Cote, Gilbert J.
    Subbiah, Vivek
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1769 - 1776
  • [8] YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
    Katayama, Yuki
    Yamada, Tadaaki
    Tanimura, Keiko
    Kawachi, Hayato
    Ishida, Masaki
    Matsui, Yohei
    Hirai, Soichi
    Nakamura, Ryota
    Morimoto, Kenji
    Furuya, Naoki
    Arai, Sachiko
    Goto, Yasuhiro
    Sakata, Yoshihiko
    Nishino, Kazumi
    Tsuchiya, Michiko
    Tamiya, Akihiro
    Saito, Go
    Muto, Satoshi
    Takeda, Takayuki
    Date, Koji
    Fujisaka, Yasuhito
    Watanabe, Satoshi
    Fujimoto, Daichi
    Uehara, Hisanori
    Horinaka, Mano
    Sakai, Toshiyuki
    Yano, Seiji
    Tokuda, Shinsaku
    Takayama, Koichi
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 1127 - 1141
  • [9] Towards precision oncology in RET-aberrant cancers
    Subbiah, Vivek
    Roszik, Jason
    CELL CYCLE, 2017, 16 (09) : 813 - 814
  • [10] RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives
    Addeo, Alfredo
    Miranda-Morales, Ernesto
    den Hollander, Petra
    Friedlaender, Alex
    Sintim, Herman O.
    Wu, Jie
    Mani, Sendurai A.
    Subbiah, Vivek
    PHARMACOLOGY & THERAPEUTICS, 2023, 242
12345